This observation is in contrast with findings in the peripheral blood that show no change in the number of lymphocytes that display CD3 and CD8 markers (total and CD8+ T cells, respectively), and may suggest that EMD 273063 effectively targets GD2 expressing tumors, and delivery of IL2 to the tumor microenvironment, resulting in expansion of CD8+ T cells, more notably CTL. Here, IL2 is linked to neoplasm.